Natera Inc (NTRA) slumped 3.79% in heavy selling after a string of recently positive corporate updates, even as the company’s strong Q2 revenue beat and broad clinical adoption of its Signatera ...
Natera Inc (NTRA) fell 5.71% after the company launched the AFT-70 NAVIGATE global phase III trial and announced multiple business milestones. The size of the drop contradicts the positive news ...
Natera Inc (NTRA) jumped 3.51% after Japan's regulatory authority approved its Signatera test as a companion diagnostic for muscle-invasive bladder cancer, creating a new growth opportunity for ...
Natera Inc (NTRA) climbed 4.34% today after reporting record Q2 2025 revenue and raising full-year guidance, driven by strength in its oncology business and rising demand for the Signatera test. ...
A court order temporarily halts Paramount's planned $110 billion acquisition of Warner Bros. Discovery as a multistate antitrust challenge moves forward. The dispute centers on whether the merger ...
Natera Inc (NTRA) fell 3.7% after a wave of profit-taking, even as recent regulatory advances including Japanese approval for its Signatera MRD test and a major cancer trial partnership signaled ...
Natera Inc. (NTRA) stock is trading at $271.45 after a modest slip during the session. The price holds above its key moving averages, reflecting ongoing momentum in the ...